Safety

Company Announcement

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Bella all Natural Issues Voluntary Nationwide Recall of Diet Capsules Labeled as Bella, Due to Presence of Sibutramine

For Immediate Release

February 22, 2018

Contact

Consumers

Bella all Natural
cabral_daisy@yahoo.com
(323)552-6263

Announcement

Bella All Natural is voluntarily recalling its Diet Capsules labeled as Bella, Lot Number MFD:10.15.2017 EXP: 10.14.2019, to the consumer level.

This recall has been initiated due to presence of sibutramine. Sibutramine is an appetite suppressant that was withdrawn from the U.S. market in October 2010 due to safety concerns. N-Desmethyl sibutramine is an active metabolite of sibutramine. Sibutramine and its active metabolites substantially increase blood pressure and/or pulse rate in some patients and may present significant health risks including heart attack, arrhythmia, and stroke. The company has not received any reports of adverse events or injuries.The product is used as a diet pill and is packaged in a plastic bottle, with 30 pills, and with the Lot Number MFD:10.15.2017 EXP: 10.14.2019. Bella was distributed in California via internet and retail.

Bella All Natural is notifying its distributors and customers by Customer Notification/Recall Communication and is arranging for return of product of all recalled products. Consumers that have Bella Diet Capsules which is being recalled should stop using immediately and return to place of purchase.

Consumers with questions regarding this recall can contact Bella all Natural by calling (323)552-6263, or e-mail address: cabral_daisy@yahoo.com on Monday-Sunday, 10 a.m. - 5:30 p.m., PST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

###

Page Last Updated: 02/23/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English